Literature DB >> 17096681

Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage.

Elisabetta Poluzzi1, Petar Strahinja, Alberto Vaccheri, Antonio Vargiu, Maria Chiara Silvani, Domenico Motola, Giulio Marchesini, Fabrizio De Ponti, Nicola Montanaro.   

Abstract

AIM: To evaluate adherence to chronic cardiovascular drug treatments, in terms of long-term persistence and dose coverage.
METHODS: General practice prescription data of antihypertensives, lipid-lowering agents, oral hypoglycaemic agents and nitrates were collected over a 5-year period (1998-2002) in a Northern Italian district (Ravenna, 350,000 inhabitants). We selected subjects (>40 years) receiving at least one prescription of the above drugs in December 1999. For each patient, we documented the regimen at the time of selection and evaluated adherence to treatment during the following 3 years in terms of persistence (at least one prescription per year) and daily coverage (recipients of an amount of medication consistent with daily treatment).
RESULTS: Fewer than 10% of the 32 068 selected subjects were naive to treatment. Antihypertensives were the most represented therapeutic category. Among patients already on treatment in December 1999, persistence was virtually complete, whereas >40% of naive patients withdrew within 1 year, except for nitrates. The rates of coverage were always much lower than the corresponding values of persistence. Coverage was significantly higher in older patients (chi(2) for trend 69.41; P < 0.001), males (odds ratio 1.30; 95% confidence interval 1.25, 1.36) and users receiving more than one therapeutic category.
CONCLUSIONS: Lack of adherence to chronic cardiovascular treatments represents an important matter of concern: although most people continued treatment over the years, less than 50% received an amount of drugs consistent with daily treatment, thus jeopardizing the proved beneficial effects of available medications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17096681      PMCID: PMC2000734          DOI: 10.1111/j.1365-2125.2006.02801.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  [Guideline for the diagnosis and treatment of unstable angina. Update 2000].

Authors:  F Crea; M Galvani; A Canonico; V Cirrincione; G Di Pasquale; F Mauri; M Penco; P Zardini; C Vassanelli; A Barsotti; G Mazzotta
Journal:  Ital Heart J Suppl       Date:  2000-12

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  European guidelines on cardiovascular disease and prevention in clinical practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Atherosclerosis       Date:  2003-11       Impact factor: 5.162

4.  Statin compliance in the Umbrian population.

Authors:  Iosief Abraha; Alessandro Montedori; Fabrizio Stracci; Mariangela Rossi; Carlo Romagnoli
Journal:  Eur J Clin Pharmacol       Date:  2003-09-24       Impact factor: 2.953

5.  Aspirin overprescription in primary cardiovascular prevention.

Authors:  Costantina Manes; Luciano Giacci; Adolfo Sciartilli; Alberto D'Alleva; Raffaele De Caterina
Journal:  Thromb Res       Date:  2006       Impact factor: 3.944

6.  Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy.

Authors:  J Larsen; A Vaccheri; M Andersen; N Montanaro; U Bergman
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

7.  High persistence of statin use in a Danish population: compliance study 1993-1998.

Authors:  John Larsen; Morten Andersen; Jakob Kragstrup; Lars F Gram
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

8.  Long-term persistence in use of statin therapy in elderly patients.

Authors:  Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

9.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  Secondary prevention of stroke in Italy: a cross-sectional survey in family practice.

Authors:  Alessandro Filippi; Angelo Antonio Bignamini; Emiliano Sessa; Fabio Samani; Giampiero Mazzaglia
Journal:  Stroke       Date:  2003-03-13       Impact factor: 7.914

View more
  6 in total

1.  Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.

Authors:  Michael H Davidson; Peter H Jones
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

2.  Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Monica Lanzoni; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Antonio Gaddi; Alberto Vaccheri; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

3.  Multidrug treatment of type 2 diabetes: a challenge for compliance.

Authors:  Roberto Miccoli; Giuseppe Penno; Stefano Del Prato
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

4.  Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study.

Authors:  Philippe Latry; Mathieu Molimard; Bernard Dedieu; Thierry Couffinhal; Bernard Bégaud; Karin Martin-Latry
Journal:  BMC Cardiovasc Disord       Date:  2011-07-26       Impact factor: 2.298

5.  Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts.

Authors:  Louise E Bartlett; Nicole L Pratt; Elizabeth E Roughead
Journal:  Patient Prefer Adherence       Date:  2018-05-16       Impact factor: 2.711

6.  Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.

Authors:  Rolf Wachter; Ana F Fonseca; Bogdan Balas; Elisabeth Kap; Johanna Engelhard; Raymond Schlienger; Sven Klebs; Sara Bruce Wirta; Karel Kostev
Journal:  Eur J Heart Fail       Date:  2019-04-11       Impact factor: 15.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.